Intra-tracheal Instillation of Budesonide to Prevent Chronic Lung Disease

NCT05364385 · clinicaltrials.gov ↗

PHASE4

Phase

UNKNOWN

Status

25

Enrollment

OTHER

Sponsor class

Conditions

Infant, Extremely Premature
Acute Lung Injury
Chronic Lung Disease of Prematurity
Budesonide

Interventions

DRUG: Infants in the study group (S/B group) will receive surfactant 2.5 mls/kg and Budesonide 0.5 mg (1mL)
DRUG: Infants in the control group (S/P group) receive placebo (Normal saline 1mL)

Sponsor

University of Arizona